Learn how to ensure that your health plan – NOT your PBM – benefits from your employees’ generic drug use. This video will explain a) how numerous PBMs are retaining a large portion of the financial benefits resulting from generic drug use; b) how most PBMs manipulate their contracts with clients to do so; and c) what your health plan must do to ensure it obtains 100% of generic drug savings. Save your corporation or union or govt health plan large sums of money by following the basic steps outlined in this video. Our consulting firm has saved our clients millions of dollars in the past year alone using the strategies described. Presenter: Linda Cahn, Esq., President of Pharmacy Benefit Consultants
Video Rating: 0 / 5

Want to Live Extra Years?

Do you use generic drugs? Are they safe? Can they save you money? Tim Colligan, Director of Pharmacy at Optima Health, shares his insights into the value of using generic drugs.

The truth behind Generic Drugs.

Want to Live Extra Years?

Tongue Depressors, 500 Count

• Tongue Depressor
• Medical Care
• Wound Care
• Medical Supplies
• Medical Equipment

Tongue depressors are 6 in x 3/4″ with smooth surfaces and clean edges. (Qty: 500)

Price: $ 6.49

Want to Live Extra Years?

Click for Vacation Video

Welcome to Generic Biotech Drugs. A generic biotech drug is a drug which is produced and distributed without patent protection. The generic biotech drug may still have a patent on the formulation but not on the active ingredient. A generic must contain the same active ingredients as the original formulation.

Brief Interruption.
Need a Vacation? Click here for Video…

By extension, therefore, generics are considered (by the FDA) identical in dose, strength, route of administration, safety, efficacy, and intended use. The FDA’s use of the word identical is very much a legal interpretation, and is not literal. In most cases, generic products are available once the patent protections afforded to the original developer have expired.

When generic products become available, the market competition often leads to substantially lower prices for both the original brand name product and the generic forms. The time it takes a generic drug to appear on the market varies. In the US, drug patents give twenty years of protection, but they are applied for before clinical trials begin, so the effective life of a drug patent tends to be between seven and twelve years.

Click for Video

Want to Live Extra Years?

Is it the Right Time to Buy Biotechnology Investments?

July has been a good month for biotech investors. Share prices in the biotech sector as measured by the NYSE Biotechnology Index are up 24% compared to the 6.6% gain for the S&P 500. Earlier in the month, Amgen (AMGN) reported better-than-expected results from a trial of its experimental bone-protecting drug denosumab in patients with advanced breast cancer. Amgen’s shares vaulted 16% on the news.

In the week just ended, the momentum in biotech shares has continued further. While a host of favorable clinical trial results was the bigger driver, a large buyout announcement added the icing to the cake.

Clinical Trial Results

Bringing back memories of the dotcom era, shares of Human Genome Sciences (HGSI) rose nearly 300% to .50 a share after the company reported favorable results for its experimental lupus drug Benlysta. Targacept (TRGT) shares more than doubled to .25 a share after its depression drug candidate met its goals in a mid-stage trial. Onyx Pharmaceutical (ONXX) reported encouraging results for its breast cancer treatment Nexavar to push its shares higher by 21%. Shares of Celgene (CELG) jumped nearly 16% after the company announced significant improvement in progression-free survival of patients taking Revlimid as a first-line treatment for multiple myeloma.

Buyout

Continuing the trend of major pharma-biotech mergers, as in Roche (RHHBY.PK)-Genentech, and Eli Lilly (LLY)-ImClone, Bristol-Myers Squibb (BMY) announced it is buying Medarax (MEDX) for a share. The Medarex takeover implies a net price tag of over billion. Medarax shares jumped nearly 90% on the announcement.

Is it too Late to Board the Biotech Bandwagon?

Given strong gains in biotech shares in recent weeks, it is logical to ask if it is too late to get on the biotech bandwagon. I believe the answer, generally speaking, is no. Notwithstanding uncertainties surrounding health care reform, the fundamentals for biotech companies are reasonably favorable. Yet, one needs to take appropriate care in getting the timing right and in choosing proper investment vehicles.

Fundamentals

Several factors favor the long-term growth of biotech companies. These include an aging population, rising incidence of cancer and other degenerative diseases, and growing recognition that biotech products offer the best solutions for management of these diseases.

Several biotech drugs like Roche’s Avastin and Amgen’s Enbrel have the potential of becoming major blockbuster drugs by 2014. Biotech companies are seeking to expand uses of their approved drugs to treat more diseases. And, unlike drugs made by major pharmaceutical companies, biotech drugs

Want to Live Extra Years?